The MMRC study was supported in part by Onyx Pharmaceuticals. Dr. Zimmerman disclosed receiving honoraria, consulting, and serving on the speakers bureau for the company.
Conference Coverage
ASCO: Transplant boosts stringent complete response rate in newly diagnosed myeloma
